Skip to content

Indivior Pharmaceuticals, Inc. INDV Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

JAN
Janus Living JAN

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's accrued manufacturing costs?
Indivior Pharmaceuticals, Inc. (INDV) reported accrued manufacturing costs of $42M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's accrued manufacturing costs changed year-over-year?
Indivior Pharmaceuticals, Inc. 's accrued manufacturing costs decreased by 6.7% year-over-year, from $45M to $42M.